RaySearch Laboratories AB (CHIX:RAYBS) Cyclically Adjusted Revenue per Share: kr26.02 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:RAYBS RaySearch Laboratories AB CHIX:RAYBS
93 GF Score
Price kr234.70
GF Value kr181.57
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is RaySearch Laboratories AB Cyclically Adjusted Revenue per Share?

RaySearch Laboratories AB CHIX:RAYBS 93 Cyclically Adjusted Revenue per Share is kr26.02 as of Mar. 2026. GuruFocus rates CHIX:RAYBS with a GF Score™ of 93/100 and a GF Value™ of kr181.57 (Modestly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

RaySearch Laboratories AB's adjusted revenue per share for the three months ended in Mar. 2026 was kr8.468. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr26.02 for the trailing ten years ended in Mar. 2026.

During the past 12 months, RaySearch Laboratories AB's average Cyclically Adjusted Revenue Growth Rate was 9.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 12.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 16.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of RaySearch Laboratories AB was 18.70% per year. The lowest was 12.50% per year. And the median was 17.15% per year.

As of today (2026-07-17), RaySearch Laboratories AB's current stock price is kr234.70. RaySearch Laboratories AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was kr26.02. RaySearch Laboratories AB's Cyclically Adjusted PS Ratio of today is 9.02.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of RaySearch Laboratories AB was 30.47. The lowest was 2.64. And the median was 7.06.


RaySearch Laboratories AB  (CHIX:RAYBs) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

RaySearch Laboratories AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=234.70/26.02
=9.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of RaySearch Laboratories AB was 30.47. The lowest was 2.64. And the median was 7.06.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


RaySearch Laboratories AB Cyclically Adjusted Revenue per Share Related Terms


RaySearch Laboratories AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for RaySearch Laboratories AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaySearch Laboratories AB Cyclically Adjusted Revenue per Share Chart

RaySearch Laboratories AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.45 17.33 17.66 17.91 25.53

RaySearch Laboratories AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.79 24.28 25.45 25.53 26.02

CHIX:RAYBS vs VEEV, BTSG, TEM: Cyclically Adjusted Revenue per Share Comparison

For the Health Information Services subindustry, RaySearch Laboratories AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RaySearch Laboratories AB Cyclically Adjusted PS Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where RaySearch Laboratories AB's Cyclically Adjusted PS Ratio falls into.


CHIX:RAYBS
93GF Score
RaySearch Laboratories AB CHIX:RAYBS
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaySearch Laboratories AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, RaySearch Laboratories AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=8.468/133.5600*133.5600
=8.468

Current CPI (Mar. 2026) = 133.5600.

RaySearch Laboratories AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 3.466 101.019 4.582
201609 3.656 101.138 4.828
201612 5.596 102.022 7.326
201703 3.716 102.022 4.865
201706 4.159 102.752 5.406
201709 3.258 103.279 4.213
201712 5.979 103.793 7.694
201803 3.391 103.962 4.356
201806 4.114 104.875 5.239
201809 4.389 105.679 5.547
201812 6.401 105.912 8.072
201903 5.041 105.886 6.358
201906 5.532 106.742 6.922
201909 4.211 107.214 5.246
201912 6.840 107.766 8.477
202003 6.092 106.563 7.635
202006 4.777 107.498 5.935
202009 3.475 107.635 4.312
202012 4.662 108.296 5.750
202103 4.728 108.360 5.828
202106 4.509 108.928 5.529
202109 3.979 110.338 4.816
202112 5.500 112.486 6.530
202203 6.040 114.825 7.025
202206 4.674 118.384 5.273
202209 6.151 122.296 6.718
202212 7.712 126.365 8.151
202303 6.714 127.042 7.058
202306 7.019 129.407 7.244
202309 7.376 130.224 7.565
202312 8.740 131.912 8.849
202403 7.502 132.205 7.579
202406 9.291 132.716 9.350
202409 8.555 132.304 8.636
202412 9.398 132.987 9.438
202503 9.675 132.825 9.729
202506 8.919 133.699 8.910
202509 9.693 133.480 9.699
202512 10.950 133.390 10.964
202603 8.468 133.560 8.468

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr26.02 mean?
RaySearch Laboratories AB (CHIX:RAYBS) has a Cyclically Adjusted Revenue per Share of kr26.02 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on RaySearch Laboratories AB and its competitors.
Is RaySearch Laboratories AB's Cyclically Adjusted Revenue per Share too high?
RaySearch Laboratories AB's current Cyclically Adjusted Revenue per Share is kr26.02. Overall, RaySearch Laboratories AB has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Cyclically Adjusted Revenue per Share compare to VEEV and BTSG?
RaySearch Laboratories AB's Cyclically Adjusted Revenue per Share of kr26.02 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Healthcare Providers & Services company?
A good Cyclically Adjusted Revenue per Share depends on the Healthcare Providers & Services industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on RaySearch Laboratories AB and its competitors. RaySearch Laboratories AB's current Cyclically Adjusted Revenue per Share is kr26.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (CHIX:RAYBS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr181.57, compared to a current price of kr234.70 — trading 29.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr26.02. RaySearch Laboratories AB's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For RaySearch Laboratories AB (CHIX:RAYBS), the current Cyclically Adjusted Revenue per Share is kr26.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?

Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued. The current stock price of kr234.70 is trading 29.3% above its estimated GF Value™ of kr181.57. GuruFocus considers RaySearch Laboratories AB to be Modestly Overvalued.

Key valuation signals for CHIX:RAYBS:

  • Cyclically Adjusted Revenue per Share: kr26.02
  • GF Value™: kr181.57 vs. price of kr234.70 (29.3% above fair value)
  • GF Score™: 93/100 with 2 warning signs

No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RaySearch Laboratories AB Business Description

Address Eugeniavagen 18C, Stockholm, SWE, 113 68
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
93GF Score

Get the complete analysis for CHIX:RAYBS

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr234.70
Price
kr181.57
GF Value